Caldera launches with $112M, former Morphic CEO and IBD drug from China - Fierce Biotech

Caldera Therapeutics launched with $112M in funding, led by former Morphic CEO. The biotech is advancing an IBD drug originally developed in China.

1/14/2026

A seasoned biotech VC looks to 2026 and sees a wave of IPOs coming - statnews.com

A veteran biotech venture capitalist forecasts a surge in IPOs by 2026, signaling renewed investor confidence in the biotech sector after a prolonged market downturn.

12/22/2025

Bruce Booth Has Seen It All in Biotech Venture Capital - WSJ

Bruce Booth, a prominent biotech venture capitalist, shares insights from his extensive experience in the industry, reflecting on trends, challenges, and opportunities in biotech investing.

12/11/2025

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - BioSpace

Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures along with additional capital from existing investors, signaling growing confidence in the company's immunotherapy pipeline and development programs.

11/18/2025

Drug developer Biogen unveils VC investment arm - Global Venturing

Biogen, a leading drug developer, has launched a dedicated venture capital investment arm, signaling its strategic move to expand beyond traditional pharmaceutical development into startup ecosystem funding.

11/6/2025

Hemab collects another $157M to go after ‘underserved’ blood diseases - biopharmadive.com

Hemab Therapeutics raised an additional $157M to advance treatments for rare, underserved blood disorders, building on previous funding to develop novel therapies targeting unmet medical needs in hematology.

10/27/2025

Atlas Venture Announces $400 Million Third Opportunity Fund - SynBioBeta

Atlas Venture has announced the launch of its $400 million Third Opportunity Fund, aimed at supporting biotech and life sciences companies in their growth and development stages.

9/11/2025

Atlas Venture: $400 Million Opportunity Fund III Closed For Supporting Biotech Innovation - Pulse 2.0

Atlas Venture has closed its $400 million Opportunity Fund III, aimed at supporting biotech innovation and advancing promising life sciences companies.

9/8/2025

Atlas Venture closes on $400m Opportunity Fund III - venturecapitaljournal.com

Atlas Venture has successfully closed its Opportunity Fund III at $400 million, marking a significant milestone for the venture capital firm focused on biotech investments.

9/5/2025

Atlas Venture Announces $400 Million Third Opportunity Fund - Business Wire

Atlas Venture has announced the launch of its third opportunity fund, raising $400 million to support its portfolio of biotech and life sciences companies.

9/4/2025

Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound - statnews.com

A biotech venture capital firm has raised a $400 million opportunity fund, signaling a potential rebound in the biotech industry amid recent market challenges.

9/4/2025

VC Atlas lands $400M to support existing biotech portfolio - Fierce Biotech

Venture capital firm Atlas has secured $400 million in new funding aimed at supporting its existing biotechnology portfolio companies rather than making new investments.

9/4/2025

Atlas' $400M growth fund will support its portfolio of biotechs - FirstWord Pharma

Atlas Venture has established a $400M growth fund aimed at supporting the continued development of its biotech portfolio companies.

9/4/2025

Atlas Venture raises $400M to invest in later-stage biotechs - The Business Journals

Atlas Venture has raised $400 million in a new fund aimed at investing in later-stage biotech companies, expanding beyond its traditional early-stage focus.

9/4/2025

Renasant Bio launches to develop kidney disease treatment - C&EN

Renasant Bio has launched as a new biotech company focused on developing treatments for kidney disease, aiming to address significant unmet medical needs in nephrology.

7/10/2025